GlassScriptPhysician profile
Lemuel W Kemp
NPI 1184109654
$1,891.91
in general payments reported to CMS, 2019-2025
26 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.79 · 2022: $87.60 · 2023: $21.65 · 2024: $696 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.92 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $271.66 | 2021-2025 | |
| Corcept Therapeutics | $215.06 | 2025 | Korlym |
| Lilly USA, LLC | $158.13 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Corium, LLC | $142.63 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $141.61 | 2024 | |
| Axsome Therapeutics, INC. | $61.66 | 2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.56 | 2024-2025 | Caplyta |
| Dexcom, INC. | $51.91 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $51.02 | 2024-2025 | |
| Noven Therapeutics, LLC | $49.05 | 2024 | Secuado |
| Amgen INC. | $43.25 | 2025 | Otezla, Repatha, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.24 | 2022 | |
| Collegium Pharmaceutical, INC. | $35.56 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.18 | 2022-2024 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Analog Devices INC. | $23.81 | 2025 | Sensinel Cpm Wearable |
| Cranial Technologies, INC | $22.43 | 2024 | Doc Band |
| Sanofi-Aventis U.S. LLC | $21.05 | 2024 | |
| Paratek Pharmaceuticals, INC. | $17.32 | 2025 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $16.28 | 2024 | Farxiga |
| Insulet Corporation | $15.41 | 2022 | |
| Exact Sciences Corporation | $14.99 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $13.98 | 2024 | Trelegy Ellipta, Arexvy |
| Tris Pharma INC | $13.84 | 2024 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $13.36 | 2024 | |
| Genentech USA, INC. | $4.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lemuel Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.